Western blot analysis. MET overexpression in 104 patients: 34/47 (72%) in adenocarcinomas, 20/52 (38%) in squamous cell carcinomas. IHC in 104 patients: 56/104 (54%) of NSCLCs consisted of 36/47 (77%) of adenocarcinomas, 19/52 (37%) of squamous cell carcinomas. Here, MET is linked to adenocarcinoma.